PMC5903093_01
Clinical course part 1: the clinical course before admission.
cnd-0008-0062-g01.jpg
PMC5903093_01_cnd-0008-0062-g01.jpg
F1
At 58 years, tolvaptan therapy was started at 60 mg/day (morning and afternoon doses of 45 and 15 mg) to treat her renal disease (Table 1; Fig. 1).
Clinical course part 2: the clinical course after admission.
cnd-0008-0062-g02.jpg
PMC5903093_01_cnd-0008-0062-g02.jpg
F2
Before admission, hypokalemia was exacerbated after starting tolvaptan therapy, and her hypertension became refractory (Fig. 2).